
BiotechTV - News SF Healthcare Week: Neurocrine Biosciences CEO Kyle Gano describes how the company's novel muscarinic agonist portfolio is rooted in novel drug design, with its lead M4 agonist in late-stage trials
Jan 15, 2026
Chapters
Transcript
Episode notes
